Research report

Depressive-like behaviour of mice lacking cellular prion protein

Vinicius M. Gadotti, Stephan P. Bonfield, Gerald W. Zamponi∗,1

Department of Physiology and Pharmacology, Hotchkiss Brain Institute, University of Calgary, Calgary T2N 4N1, Canada

ARTICLE INFO

Article history:
Received 11 September 2010
Received in revised form 23 February 2011
Accepted 4 March 2011
Available online 23 March 2011

Keywords:
Prion protein
Depression
Knockout mice
Forced swimming test
Tail suspension test
Nmda receptor

ABSTRACT

Cellular Prion Protein (PrPc) is known to mediate a protective role in several neurological conditions such as ischemia and epilepsy. However, so far, little information is available concerning the role of PrPC in psychiatric disorders such as depression. Here, we have used PrPC null mice to examine a putative role of PrPC in depressive-like states. Prion protein null mice exhibited depressive-like behaviour when compared to wild-type mice in both the Forced Swimming Test (FST) and Tail Suspension Test (TST). The clinical antidepressant drug imipramine and the NMDA receptor antagonist MK-801 reversed the depressive-like behaviour observed for knockout mice in the TST. The present data thus indicate that PrPC exerts a critical role in modulating the depressive-like state in mice, reinforcing the notion that PrPC might be associated with alterations in mood disorder states, and suggests a possible role of PrPC as a potential drug target for treating depressive disorders.

© 2011 Elsevier B.V. All rights reserved.

1. Introduction

Depression is a common, recurring psychiatric disorder that ranges in severity from mild to very severe. The attendant economic costs to society and personal burden to patients and families are enormous. The World Health Organization estimates that major depression is now the fourth most important cause worldwide of loss in disability-adjusted life-years and will be the second most important cause by 2020 [24]. Although pharmaco-therapy of depression includes a battery of drugs, the efficacies of those drugs are unsatisfactory, because they exert multiple unwanted side effects and their antidepressant mechanism remains incompletely understood [23]. However, it is clear that dysfunction of the brain monoamine circuitry in the limbic system (e.g., serotonin (5-HT), dopamine (DA) and noradrenaline (NA)) is likely to play a role in the pathophysiology of depressive disorders [36]. Moreover, recent evidence has linked other hippocampal neurotransmitters, such as glutamate, to the pathogenesis of depression [14].

Prions are proteinaceous infectious agents that play important role in the etiology of transmissible spongiform encephalopathies (TSEs). These disorders arise from a progressive conversion of the normal, non pathological cellular prion protein (PrPC) into a misfolded, infectious scrapie form (PrPSc) that is neurotoxic. While the role of PrPSc in TSEs is well established, less is known about the physiological role of PrPC, a protein that is widely expressed in the brain and other tissues [for review see 37]. Our laboratory has recently shown that the absence of PrPC alters N-Methyl-D-Aspartate (NMDA) receptor function in hippocampal neurons [15], and hence, we hypothesized that PrPC might regulate depressive-like behavior by virtue of altered NMDA receptor activity in the hippocampus. Indeed, there are several collorary lines of investigations that suggest possible links between prion proteins and depression. For example, Weis et al. [35] recently showed that PrPC-positive glial cells were significantly reduced in cingulate gyrus white matter of bipolar disorder and patients and major depression patients. Moreover, there appears to be comorbidity between prion diseases such as Creutzfeld–Jacob disease and depression as shown by several case reports [9,12,13,34].

The aim of the present study was to investigate the response of PrPC null mice in well-established behavioural models that predict depressive activity, such as the Forced Swimming Test (FST) and the Tail Suspension Test (TST). Here, we show that PrPC-null mice exhibit depressive-like behaviour in these tests, and that this behaviour can be reversed by a classical tricyclic antidepressant or by an NMDA receptor antagonist.

2. Materials and methods

2.1. Animals

All experiments were conducted following the protocol approved by the Institutional Animal Care and Use Committee (protocol #M09099) and all efforts were made to minimize animal suffering. A total of 125 adult male C57BL/6J (wild type and PrP null mice 10 weeks old, weighing 25–30 g) were used. Animals were housed in a maximum number of five per cage (30 cm × 20 cm × 15 cm) with food and water.
ad libitum. They were kept in 12 h light/dark cycles (lights on at 7:00 a.m.) at a temperature of 23 ± 1°C. All manipulations were carried out between 11:00 a.m. and 3:00 p.m. Separate cohorts of mice were used for each test and each mouse was used only once. The observers were blind to the experimental conditions. Mice with a targeted disruption of the prion gene (PrP) of the Zurich 1 strain [5] were obtained from the European Mouse Mutant Archive (EM:0158; European Mouse Mutant Archive, Rome) and out-bred to generate PrP−/− (PrP-null) littermates used in the experiments. Genotyping was performed by gel electrophoresis of PCR products obtained from genomic DNA that was isolated from tail samples. Primers and PCR parameters were similar to those used previously [5].

### 2.2. Drugs and treatment

The following drugs were used in the study: Imipramine and MK-801 (Sigma Chemical Company, St. Louis, MO, USA). All drugs were dissolved in PBS and administered by intraperitoneal (i.p.) route (30 min before TST, FST or OF) in a constant volume of 10 ml/kg body weight. Appropriate vehicle-treated groups were also assessed simultaneously.

#### 2.3. Forced swimming test (FST)

Mice were individually forced to swim in an open cylindrical container (diameter 10 cm, height 25 cm), containing 19 cm of water at 25 ± 1°C; the total duration of immobility during a 6 min test was scored as described previously [28]. Each mouse was judged to be immobile when it ceased moving its limbs in any kind of swimming action and remained motionless floating in the water, while making the necessary movements to keep its head above water. Immobility time was measured for C57BL/6J wild type and PrP−/− mice for the entire 6 min they spent in the water in order to evaluate depressive-like behaviour.

#### 2.4. Tail suspension test (TST)

The total duration of immobility induced by tail suspension was measured according to the method described by Steru et al. [32] with minor modifications. Briefly, mice were both acoustically and visually isolated and suspended 50 cm above the floor by adhesive tape placed approximately 1 cm from the tip of the tail. Immobility times in the C57BL/6J wild type and PrP−/− mice were scored visually and recorded manually with a chronometer for 6 min in order to evaluate depressive-like behaviour. Each mouse was judged to be immobile when it ceased struggling and remained without any body movement (total immobility time). A decrease in the duration of immobility is indicative of an antidepressant-like effect. Mice were treated with imipramine (10 mg/kg, i.p.), or MK-801 (0.01 mg/kg, i.p.) or with vehicle (PBS, 10 ml/kg, i.p.) 30 min prior to each tail suspension experiment was carried out. We chose the TST rather than FST for drug studies because of the larger depressive effect observed with the PrP−/− mice in the TST.

#### 2.5. Open-field test

Ambulatory behaviour was assessed in an open-field test as described previously [4]. The apparatus consisted of a wooden box measuring 40 cm × 60 cm × 50 cm with a frontal glass wall. The floor of the arena was divided into 12 equal squares and placed in a quiet room. The test room was illuminated with soft white light. Animals were placed in the rear left square of the wooden box and were left to free to explore the 12 squares freely for 6 min, during which time the experimenter counted the number of squares that the animal had crossed with all of its paws. Mice were treated with imipramine (10 mg/kg, i.p.) or MK-801 (0.01 mg/kg, i.p.) or with vehicle (PBS, 10 ml/kg, i.p.) 30 min prior to each evaluation. After each individual experiment, the apparatus was cleaned with a 70% alcohol solution and dried.

#### 2.6. Statistical analysis

Data were presented as means ± SEM and evaluated by t-tests or two-way analysis of variance (ANOVA) followed by a Duncan test when appropriate. A value of \( P < 0.05 \) was considered to be significant.

### 3. Results

#### 3.1. Depressive-like behaviour of PrP−/− mice in the FST and TST

The results depicted in Fig. 1 show the behavioural responses of wild type mice and mice lacking PrP−/− when assessed in both FST and TST. As shown in Fig. 1, PrP−/− mice exhibited a significantly elevated immobility time in both the FST (panel A) and in the TST (panel B) compared to their wild type littermates, (*t*-test). Of particular note, in the open-field test we found that there was a significantly higher number of crossings of PrP−/− mice compared to the expected normal ambulatory behaviour of the wild type animals (Fig. 1C). These data show that depressive-like behaviour of PrP−/− mice in these tests was not due to an unspecified effect of the gene knockdown, such as impairment of locomotor activity.

#### 3.2. Effect of imipramine on mice depressive-like state in the TST

We then assessed whether a classical antidepressant drug could reverse the depressive-like behaviour observed for PrP−/− mice in the TST. Fig. 2 shows that the administration of imipramine (10 mg/kg, i.p., a tricyclic antidepressant) 30 min before the TST
Imipramine treated wild-type mice. The two-way ANOVA revealed a significant effect of genotype \( [F(1,21) = 74.29, P < 0.01] \) treatment \( [F(1,21) = 1.66, P = 0.21] \) and the genotype X-treatment interaction \( [F(1,21) = 27.43, P < 0.01] \). Therefore, these data demonstrate that the behaviour observed in Fig. 1 indeed bears the standard characteristics of depression (i.e. prolonged immobility, apathy, decreased effort to swim) rather than immobilization caused by motor deficits.

3.3. Effect of MK-801 on wild-type and PrP−/− mice in the TST

To determine if a mechanism involving NMDA-receptor activity may be involved in the depressive-like behaviour exhibited by PrP−/− mice in the TST, we delivered the NMDA receptor antagonist MK-801 through an i.p. route to both wild-type and PrP−/− mice. Fig. 3 shows that the administration of MK-801 (0.01 mg/kg, i.p.) 30 min before the TST decreases the immobility time in both wild-type mice and PrP−/− mice. The two-way ANOVA revealed a significant effect of genotype \( [F(4,54) = 11.5, P = 0.03] \) and the genotype X-treatment interaction \( [F(2,01) = 7.7, P < 0.001] \). The MK-801 mediated reversal of the depressive like state seen in PrP null mice is consistent with observations that NMDA receptor activity is upregulated in the absence of PrP [16], and provides a functional link between this NMDA receptor activity and altered behavioural states.

3.4. Effects of Imipramine or MK-801 on spontaneous locomotor activity of wild-type and PrP−/− mice

Imipramine and MK-801 were tested in the locomotor activity apparatus in order to test whether the variation in the immobility time evaluated in the tail suspension test could be linked to a modification of the spontaneous locomotor activity rather than an antidepressant-like effect of the drugs. The results presented in Fig. 4 show that the administration of imipramine or MK-801 did not produce any effect in the ambulatory behaviour of wild-type (Fig. 4a) or PrP−/− (Fig. 4b) animals.

4. Discussion

It is becoming increasingly clear that cellular prion protein is an important neuromodulator [37], but there have been few studies showing its possible role in mood disorders. Our data demonstrate that the PrP−/− mice exhibit an increase in immobility time compared to wild-type mice in both the FST and in the TST. Both of these tests have been developed to evaluate depressive-like behaviours in rodents and their usefulness is based on the observation that immobility time is reduced by many different classes of antidepressants [3,28]. Although these tests are typically employed to screen for new antidepressant drugs [8], they have been widely used to investigate depressive-like behaviour that may also be induced by drugs [7,26] or by gene knock-down [2,11]. It is important to emphasize that the depressive-like behaviour of PrP−/− mice in these tests was not due to motor dysfunction, as a general increase of ambulatory activity was observed for PrP−/− mice in which the authors used the FST as an acute stress protocol.
In our hands, the tricyclic antidepressant imipramine was able to reverse the depressive-like behaviour observed for PrP<sup>−/−</sup> mice. The efficacy of this antidepressant to decrease the immobility time was greater in PrP<sup>−/−</sup> mice than the effect observed for wild-type mice. Results from Klingenstein et al. [16] indicate that tricyclic antidepressants display structure-dependent antiprion effects, and enhanced the antiprion effects of quinacrine in a cell culture model of prion disease. The ability of imipramine to decrease in vivo immobility is likely related to its in vitro antiprion effects.

Glutamate is the excitatory neurotransmitter controlling synap tic excitability and plasticity in most brain circuits, including those areas thought to be involved in depression such as the hippocampus and the amygdala [27]. The NMDA receptor is one of the major ionotropic glutamate receptors, and its known role in depression together with our previous findings showing that PrP<sup>−/−</sup> null mice. NMDA receptor antagonists have been proposed as potential antidepressants and reportedly exhibit antiprion effects in both humans [10,19,21] and rodents [17,22,29]. It is important to note that not even conventional antidepressants that act through the monoaminergic system may ultimately signal to NMDA receptors, thus leading to the same functional effects as NMDA antagonists [31].

There is now a growing body of scientific literature describing the involvement of the hippocampus in the neurobiology of such mood disorders, mainly based on observations that similar neurochemical and morphological changes can be found in the hippocampus of both depressed humans and stress-induced depressed animals, and these changes can be prevented and/or reversed by antidepressant treatment [6,20,30,33]. Impairment of neuroplasticity in the hippocampus, amygdala and cortex is hypothesized to be the mechanism by which cognitive function, learning, memory and emotions are altered in depression [20]. While much attention has been focused on hippocampal serotonergic and noradrenergic systems, recent evidence has linked other hippocampal neurotransmitters, such as glutamate and nitric oxide (NO) to behavioural changes induced by stress and subsequently observed in depressed animals [14]. Furthermore, several studies indicate that there is a disproportionate amount of serotonin dysregulation in prion diseases and that prion-mediated cytotoxicity may be blocked by NMDA receptor antagonists [for review see 1]. In this context, our findings fit nicely with our previous work showing augmented NMDA receptor function in hippocampal neurons of PrP<sup>−/−</sup> mice [15].

In summary, results from the present study show, for the first time, that PrP<sup>−/−</sup> mice plays a role in depression through a mechanism that is consistent with an inhibition of the glutamatergic system through NMDA receptors. This in turn may suggest a molecular mechanism underlying the well-established co-morbidity between early onset Creutzfeldt–Jakob disease and depression [9,12,13,34].

5. Competing interests

The authors declare that they have no competing interests.

6. Author contribution

VMG designed and performed experiments, data analysis and wrote the article. SPB performed experiments and edited the manuscript. GWZ supervised the research project and edited the manuscript. The authors read and approved the final manuscript.


